Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Click on the paperclip at the top of the page to add, remove or edit files. If possible, please add a row to the table below to allow easy access to your slides.

 

9 May 2012

PUW1

Joanna

Immunology

16 May 2012

WCJ

Angelina

Zidovudine PK/PG

23 May 2012

PUW2

Jig

LMWH in pregnancy

30 May 2012

No meeting



6 June 2012

PUW1

Joe

Antimicrobial PKPD

13 June 2012

PUW1

Terry Shepard

Geriatric PKPD

20 June 2012

PUW2

Rollo/Joanna

Immunology modelling

27 June 2012

No meeting



4th July 2012

No meeting



11th July 2012

PUW2

Julie

PAGE review

18th July 2012

PUW2

Katie

Gentamicin in burns

12/10/12 1pm

WCA

Rollo

Modelling of the immune reconstitution post BMT

19/10/12 1pm

PUW3

Joe

Prague Biometrics 2012;68:902-11

26/10/12 1pm

PUW3

Charlotte

NAPPA (Beta lactam pharmacokinetics/pharmacodynamics) plans

2/11/12 1pm

PUW3

Eva

Neogent (developing Bayesian therapeutic drug monitoring) progress

9/11/12 1pm

PUW3

Joanna

Inference methods course review

16/11/12 1pm

PUW2


General discussion

23/11/12 1pm

PUW3

Julie

Covariate selection methods in pharmacokinetic modelling

30/11/12 1pm

PUW3

Julie

NCA versus modelling in phase I studies for drugs with long half-life

7/12/12 1pm

PUW3


Goldacre talk

14/12/12 1pm

PUW3

Lilia

Neutropenia post-BMT

...

1/9/14

LGSR

Joe

Antimicrobial PKPD   IDM_clinpharm_Standing_2014.pdf

8/9/14 meeting starts 2pm

Levinski

Julie

DDMore language

15/9/14

LGSR

Paul

Pharmacogenetics of diclofenac

22/9/14

LGSR

Yucheng

Count data models and introduction to Pirana

29/9/14

LGSR

Andreas

Gabapentin PKPD in paediatric neuropathic pain

6/10/14

LGSR

Liana

Tyrosine kinase inhibitor effects in polycystic kindney disease

13/10/14

LGSR

Joanna


20/10/14

LGSR

Rollo

Short-term neutrophil and lymphocyte HSCT models

27/10/14

LGSR

Eva

NeoGent PKUK practice

3/11/14

LGSR

Seb

Item Response Theory: Application to NLME

10/11/14

LGSR

Joe

A new mechanistic model for antiretroviral pharmacodynamics 

17/11/14

LGSR

Alberto

Anaesthesia depth with 3 different EEG measures

24/11/14

LGSR

Suzanne Reeves

Mechanisms underpinning antipsychotic sensitivity in Alzheimer's disease

1/12/14

LGSR

Deji

Mixed Effect Modelling in Hep C-HIV coinfected children

8/12/14 meeting starts at 2pm

LGSR

TBC

To be confirmed

15/12/14

LGSR

Morris

Understanding the determinants of drug exposure and pharmacokinetic variability in tuberculosis patients

...

7/9/15PUW3AiweiDexmeditomidine PKPD
14/9/15PUW3EvaMeropenem in late onset sepsis and meningitis in neonates
21/9/15PUW3LudoDexmeditomidine PKPD (in veterinary subjects)
28/9/15PUW3BenModelling HCMV
5/10/15PUW1SuzanneAmisulpride PK update
12/10/15PUW1David MoorePKPD in TB
19/10/15PUW1JoePersonalised medicine with PKPD
26/10/15PUW1Imperial GroupAntimicrobial decision support
2/11/15PUW1

9/11/15PUW2RolloPhD viva prep talk
16/11/15PUW2EvaIRT for neonatal sepsis
23/11/15PUW2FrankPKPD in malaria
30/11/15PUW2Morris

PBPK Modelling in TB

7/12/15PUW2LianaPKD PKPD
14/12/15PUW2Pratima ChowdaryIndividualised dosing in haemophilia

Date


Location*

Presenter

Topic

1/2/16PUW3DejiHIV models in children
4/4/16PUW2MorrisModel-based translational research in tuberculosis

4/7/16

PUW2

AlbertSiRNA PD in neuroblastoma
6/2/16PUW1CharlotteUpdate on NAPPA

6/6/16

PUW2

No meetingPAGE
7/3/16PUW3FrankIn vitro TB PD

9/5/16

PUW3

Joy DawesMorphine and dexmeditomidine PK in children
11/4/16PUW3Oliver StirrupAdult NLME in HIV under HAART

11/7/16

PUW2

No MeetingTo be rescheduled: Min - NAPPA amoxicillin/co-amoxiclav PK results

13/6/16

PUW2

GeorgieFlucloxacillin PK: Neonatal results from NAPPA
14/3/16PUW3JulieBayesian inference in high-throughput pharmacogenetics
15/2/16PUW3YuchengCount data modelling of BATA

16/5/16

PUW3

JulieJoint modelling of plasmatic and intracellular concentrations of Tenofovir (TDF) and Emtricitabine (FTC) - The COPHAR3 trial
18/1/16PUW3Planning meeting
18/4/16PUW3BenIncorporating immunity into CMV models

20/6/16

PUW2

Dan Wright

Model-based dose prediction: the curious case of allopurinol

21/3/16PUW2DejiModelling poor immune response in HIV-infected children
22/2/16PUW3BenCMV model update

23/5/16

PUW2

LetiziaPBPK in TB
25/1/16Levinski roomJoeScaling in PK and PD
25/4/16PUW3Per Olsson

Life as a pharmacometrics consultant

27/6/16

PUW2

Salvo

Neonatal antimicrobial PK

29/2/16PUW2FabriziaPKPD in neurology

...

Date

Location*

Presenter

Topic

19/12/16 (12:00)PUW1CharlotteUpdate on NAPPA
16/1/17 PUW4FrankPractice MRC interview
23/1/17PUW4JoeFLACSAM PK results
30/1/17PUW4AllPaediatric sample size discussion
6/2/17PUW4FrankUpdate on treosulfan/TB work
13/2/17PUW4Mike and SophidaMRes project outline
20/2/17PUW2BenCMV PD
27/2/17PUW2CharlotteNAPPA update
6/3/17PUW2MorrisRationale for dose selection in tuberculosis: how to scale from mouse to human?
13/3/17PUW2Benjamin Blaise
iSleep/iCare - real-time metabolic support for personalized intensive care
20/3/17PUW2

27/3/17PUW2Aubrey CunninghamAdjunctive therapy for severe malaria
3/4/17PUW2BelenPhD update
10/4/17PUW2

24/4/17PUW1Annegret Dahlmann-noorPKPD in ophthalmology
8/5/17PUW1Paul BaverelTralokinumab, an investigational anti-IL13 monoclonal antibody: PK & exposure-response modeling to bridge adult and paediatrics clinical development plan
15/5/17PUW1MorrisTB modelling PAGE practice
22/5/17PUW1BenCMV modelling ESPID practice
5/6/17PUW1
No meeting
12/6/17 (12:00)PUW3AllPAGE review
19/6/17PUW1LudoHFIM progress
26/6/17PUW1Maria ScarpaEnd-user acceptability of orodispersible films (ODF) for delivery of medicine
3/7/17PUW1

10/7/17PUW1

17/7/17PUW1

...

8/1/18PUW 4planning meeting
15/1/18PUW 4
Haifa
Posaconazole study protocol
22/1/18PUW 4FrankVancomycin PKPD
29/1/18PUW 4DaganResults from ABDose
5/2/18PUW 4ShanSalbutamol PKPD
12/2/18PUW 4DionnaCoMPLEX mini project
19/2/18PUW 3

26/2/18PUW 3BernTB-PRACTECAL trial PK-PD study design
5/3/18Levinski 12:00 startAyeshaRituximab PKPD
12/3/18PUW 3BenStatistical Challenges in T Cell Receptor Repertoire Immunophenotyping
19/3/18PUW 3JoePosaconazole PK
26/3/18PUW 1WatyMachine learning approaches
9/4/18PUW 3

16/4/18PUW 3planning meeting
23/4/18PUW 3no meeting ECCMID
30/4/18PUW 3JigAnticoagulant PKPD in haemodialysis
14/5/18PUW 3FrankModelling progress in TB
21/5/18PUW 3no meeting PK course
4/6/18PUW 3MaddliePhD introduction: PKPD modelling of sedative and analgesic effects
11/6/18PUW 3Komal BhatiaInfant growth in urban informal settlements (slums) in Mumbai, India
18/6/18PUW 3ShanPsoriasis PKPD modelling
25/6/18PUW 3Oleg VolkovOptimal design in PKPD
2/7/18PUW 3BenCMV modelling
9/7/18PUW 3JulieModel-based bioequivalence




3/9/18PUW 3planning meeting
10/9/18PUW3FrankModelling of in vitro antimicrobial experiments
17/9/18PUW3no meeting
24/9/18PUW3SatveerNIHR practice psoriasis TDM
1/10/18PUW1OfranNIHR practice
8/10/18PUW1JulieDynamic individual predictions of biomarker profiles and survival in Oncology with Stan, Monolix and Nonmem
15/10/18PUW1

22/10/18PUW3Rashmi KulkarniMonitoring oxidative stress enables predictions of personalised glucose
targets in diabetic patients
29/10/18PUW3

5/11/18PUW3James Yates
Modelling nonclinical efficacy data for immune-oncology treatments
12/11/18PUW3FrankVancomycin PKPD in children
19/11/18PUW1JohnPhD introduction - nlme in vaccine development
26/11/18LevinskiSoumyaPhD introduction
3/12/18PUW3JayaNeonatal vancomycin CSF PK
10/12/18PUW3Daren AustinOptimised dose for WHO weight bands
7/1/19PUW3Planning meeting
14/1/19PUW3JoeBSAC Antimicrobial chemotherapy meeting practice
21/1/19PUW3

28/1/19PUW3MaddlieClonidine/fentanil PK update
4/2/19PUW1journal club
11/2/19PUW1FrankPredicting clinical outcome in TB
18/2/19PUW1CharlotteNAPPA overview
25/2/19PUW3
Phil Tresadern
popypkpd introduction
4/3/19PUW3SilkePhD work summary
11/3/19PUW3FerranPK paper picking with ML
18/3/19PUW3MaddliePKPD of sedation in neonates
25/3/19PUW3JudePhD Introduction
1/4/19PUW1SoumyaRituximab PD in BMT
8/4/19LEWINSKYZoePhD Introduction
15/4/19PUW3no meetingECCMID
13/5/19PUW3Claire Deakin
Modelling long-term outcomes and estimating treatment efficacy in a rare rheumatic disease
20/5/19PUW3HaifaCaspofungin PK in ECMO
3/6/19PUW1

10/6/19LEVINSKYno meeting
17/6/19PUW3AllPAGE review
24/6/19PUW3CintiaPaediatric Clinical Pharmacology in Buenas Aires
1/7/19PUW3Wen YaoPKPd in Malaysia
8/7/19PUW3JoeTreo PKPD
15/7/19PUW3MaddlieUpgrade practice

...

12/1/22PUW4/ microsoft teamsMarie Sjölin Wijk
24/1/22PUW4/microsoft teamsStefano
31/1/22PUW4/microsoft teamsAndrew Mead
7/2/22PUW3/microsoft teamsHuiMachine learning based model fitting
14/2/22PUW3/microsoft teamsCarolBivalirudin PKPD
21/2/22PUW3/microsoft teamsZoePosaconazole PKPD
28/2/22PUW3/microsoft teamsNajlaFosfomycin hollow fibre
7/3/22PUW3/microsoft teamsVicky SmithAutomated parameter extraction
14/3/22PUW3/microsoft teamsAkosua

FLARE trial PKPD

21/3/22PUW3/microsoft teamsFanFavipiravir PKPD
28/3/22PUW3/microsoft teamsEmmaAntimicrobials update
4/4/22PUW3/microsoft teams

25/4/22PUW3/microsoft teamsJudeTacrolimus PKPD
9/5/22PUW3/microsoft teamsHelen ShawPharmacokinetic Challenges for a Children’s Medicine Company
16/5/22PUW3/microsoft teams

23/5/22PUW3/microsoft teamsAmanda GweePaediatric PKPD down under
6/6/22PUW3/microsoft teamsZhonghuiProgress with GA modelling
13/6/22PUW3/microsoft teamsFanFavi update
20/6/22PUW3/microsoft teamsSoumyaB cell dynamics in BMT
27/6/22PUW3/microsoft teamsJamie DeanIntroducing the Computational Radiation Biology and Oncology Lab
4/7/22PUW3/microsoft teams

11/7/22PUW3/microsoft teams

18/7/22PUW3/microsoft teamsEmmaPredicting antimicrobial susceptibility to blood culture results

microsoft teams
5



16/
9
1/
2212/9/22
23PUW3/ microsoft teams
Jeff BarrettModel-informed Pediatric Drug Development
SoumyaPhD overview/viva practice
23/1/23PUW3/microsoft teamsShanAdalimumab PKPD
30/1/23PUW3/microsoft teams
Akosua19/9/22
Suzanne
SARS-CoV-2 viral dynamics
Piperacillin-tazobactam PKPD
6/2/23PUW3/microsoft teamsVickyPhD update
13/2/23PUW3/microsoft teamsLudo/AndrewModelling the effect of Antimicrobial use in poultry on AMR risk in 3 Asian countries / Optimized dosing regimens for the combinations of sulfonamides and trimethoprim in veterinary medicine
20/2/23PUW3/microsoft teamsHuiPhD update
27/2/23PUW3/microsoft teamsJudeTacrolimus PKPD
6/3/23PUW3/microsoft teams

13/3/23PUW3/microsoft teamsRachelProject introduction
20/3/23PUW3/microsoft teamsNajlaSystematic review
27/3/23PUW3/microsoft teamsEmmaAntibiotic prescribing in remote versus face-to-face consultations for acute respiratory infections in English primary care: An observational study using TMLE
17/4/23PUW3/microsoft teamsVickyUpgrade talk
24/4/23PUW3/microsoft teamsNajlaAntimicrobial PKPD systematic review
15/5/22PUW3/microsoft teamsJoePanoramic practice
22/5/22PUW3/microsoft teamsJoeFDA talk practice
5/6/23PUW3/microsoft teamsSimone Perazzolo Introduction to the SAAM2 software
12/6/23PUW3/microsoft teamsHuiPAGE meeting practice
19/6/23PUW3/microsoft teamsHuiPhD upgrade
26
/9/22PUW3/microsoft teamsFanUpgrade practice3/10/22PUW3/microsoft teamsNajlaUpgrade practice10/10/22PUW3/microsoft teamsEmma

Antibiotic prescribing and remote consultations in primary care

17/10/22PUW3/microsoft teamsOfranTLMEs24/10/22PUW3/microsoft teamsFrankACoP practice31/10/22PUW3/microsoft teamsReyaPKUK practice7/11/22PUW3/microsoft teamsAllACoP/PKUK review14/11/22PUW3/microsoft teamsJigFellowship chalkboard21/11/22PUW3/microsoft teams5/12/22PUW3/microsoft teamsDolapo OdujinrinIntroduction to PhD project12/12/22PUW3/microsoft teams
/6/23PUW3/microsoft teamsPAGE
3/7/23PUW3/microsoft teamsWCP
10/7/23PUW3/microsoft teamsRachel Clapham PopPk of edoxaban

PUW3/microsoft teams


5/9/22PUW3/ microsoft teamsJeff BarrettModel-informed Pediatric Drug Development
12/9/22PUW3/microsoft teamsAkosuaSARS-CoV-2 viral dynamics
19/9/22PUW3/microsoft teams

26/9/22PUW3/microsoft teamsFanUpgrade practice
3/10/22PUW3/microsoft teamsNajlaUpgrade practice
10/10/22PUW3/microsoft teamsEmma

Antibiotic prescribing and remote consultations in primary care

17/10/22PUW3/microsoft teamsOfranTLMEs
24/10/22PUW3/microsoft teamsFrankACoP practice
31/10/22PUW3/microsoft teamsReyaPKUK practice
7/11/22PUW3/microsoft teamsAllACoP/PKUK review
14/11/22PUW3/microsoft teamsJigFellowship chalkboard
21/11/22PUW3/microsoft teams

5/12/22PUW3/microsoft teamsDolapo OdujinrinIntroduction to PhD project
12/12/22PUW3/microsoft teams









4/9/23PUW3/ microsoft teamsplanning meeting
11/9/23PUW3/microsoft teamsFrankTB modelling update
18/9/23PUW3/microsoft teamsZharaAntimicrobial PKPD
25/9/23PUW3/microsoft teamsLizzyProposal overview 
2/10/23PUW1/microsoft teamsJig PatelFellowship practice
9/10/23PUW1/microsoft teamsJan StefanNONMEM tips and tricks
16/10/23PUW1/microsoft teamsRobAntimicrobial TDM Pro/con debate
23/10/23PUW1/microsoft teamsDolapoInvestigating mechanistic modelling approaches for individualised dosing of cancer therapeutics.
30/10/23PUW1/microsoft teamsFan Ciclosporin
6/11/23PUW1/microsoft teamsJoyNeonatal sedative maturation functions
13/11/23PUW1/microsoft teamsOliverCART preclinical modelling
20/11/23PUW1/microsoft teamsHuiAutomated model building update
27/11/23PUW1/microsoft teamsLizzyRituximab PKPD
4/12/23PUW1/microsoft teamsNajlaSystematic antimicrobial PKPD review
11/12/23PUW1/microsoft teamsAndrew MeadUpdate on antimicrobial PKPD


8/1/24PUW3/ microsoft teamsplanning meeting
15/1/24PUW3/ microsoft teamsHuiInfection seminar
22/1/24PUW1/microsoft teamsCharlottePhD plan
29/1/24PUW3/microsoft teamsMartin JohnsonMachine learning in PKPD
5/2/24PUW3/microsoft teamsJudeTacrolimus PK
12/2/24PUW3/microsoft teams

19/2/24microsoft teamsShengyuanAntiviral PKPD
26/2/24microsoft teamsVickyNLP update
4/3/24PUW3/microsoft teamsOliverCART update
11/3/24PUW1/microsoft teamsFanCiclosporin PK
18/3/24PUW1/microsoft teamsJigAnticoagulant PKPD
25/3/24PUW1/microsoft teamsOrlaghNIHR outline
8/4/24PUW1/microsoft teamsPlanning meeting
15/4/24PUW1/microsoft teamsNo meeting
22/4/24PUW1/microsoft teamsHiieExenatide PKPD
29/4/24PUW1/microsoft teamsAbigailPreclinical antimicrobial PKPD
13/5/24PUW1/microsoft teamsCharlotte TBSTOP PKPD
20/5/24PUW1/microsoft teamsYawenVincristine PKPD
3/6/24PUW1/microsoft teamsVickyNLP/PKPDai
10/6/24PUW1/microsoft teamsHuinlmixr2auto
17/6/24PUW1/microsoft teamsShengyuanPANORAMIC PD model
24/6/24PUW1/microsoft teams

1/7/24PUW1/microsoft teamsAndrewCombination antimicrobial PKPD
8/7/24PUW1/microsoft teamsFanImmunoglobulin PD


2/9/24PUW3/ microsoft teamsplanning meeting
9/9/24PUW3/ microsoft teamsRohan BeneckeMetformin Dosing in Obese HIV patients
16/9/24PUW3/microsoft teamsPaolo DentiImportance of BOV
23/9/24PUW3/microsoft teamsHuiUpdate following UPSS
30/9/24PUW?/microsoft teamsRobVancomycin real time PK
7/10/24PUW2/microsoft teamsJudeTacrolimus update
14/10/24PUW1/microsoft teamsHiieNovel antimicrobial modelling approach
21/10/24PUW1/microsoft teamsCharlotte5-FC update
28/10/24PUW1/microsoft teamsArwaDrug-radiotherapy combinations
4/11/24PUW1/microsoft teamsVickyTable extraction and PKPDAI update
11/11/24PUW?/microsoft teamsPKUK practiceYawen, Arwa, Shengyuan
18/11/24PUW2/microsoft teamsShengyuanSARS-CoV-2 viral dynamics
25/11/24PUW1/microsoft teamsJigRISAPS trial analysis
2/12/24PUW2/microsoft teamsNajlaAmikacin PK in neonates
9/12/24PUW2/microsoft teamsYawenAntimicrobial PKPD
16/12/24PUW3/microsoft teamsDolapoDose Selection Strategies for CAR-T Therapy in Oncology